Collaboration with The Kennedy Institute in Oxford to perform CyTOF on the clinical trial samples.


Collaboration with collaboration with Daniella Ungureanu’s group at the Medical Systems Biology Group (Taipale group) in Finland to examine the molecular aspects of ROR1 antagonism.


IUK Grant to develop the project titled: “First in class to first in human: Harnessing physiological regulation mechanisms to enhance safety and efficacy of next generation bispecific antibodies.

More in this section

Our board

Find out more about our team

Read more

Our history

Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovations from UCL, London UK.

Read more